Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0014070 (
encephalomyelitis
)
13,017
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Genetic disruption of
death receptor 6
(
DR6
) results in enhanced CD4+ T cell expansion, Th2 differentiation, and humoral responses after stimulation. However, the in vivo consequences of
DR6
targeting (
DR6
-/-) during the initiation and progression of inflammatory autoimmune disease are unclear. Using a myelin oligodendrocyte glycoprotein (MOG(35-55))-induced model of experimental autoimmune
encephalomyelitis
,
DR6
-/- mice were found to be highly resistant to both the onset and the progression of CNS disease compared with wild-type (WT) littermates.
DR6
-/- mice exhibited fewer inflammatory foci along with minimal demyelination and perivascular cuffing of inflammatory cells. Consistent with these observations, mononuclear cell infiltration, including CD4+ T cells and macrophages, in the spinal cord of
DR6
-/- mice was dramatically reduced. Furthermore, CD4+ T cells from
DR6
-/- mice exhibited profoundly reduced cell surface expression of VLA-4 before and after stimulation. Compared with WT mice,
DR6
-/- mice exhibited significantly increased autoantigen-induced T cell proliferative responses along with greater numbers of IL-4-producing and similar or slightly higher numbers of IFN-gamma-producing CD4+ T cells.
DR6
-/- CD4+ T cells secreted higher levels of the Th2 cytokine, IL-4, and similar levels of the Th1 cytokine, IFN-gamma, compared with WT cells. Taken together, our data demonstrate that
DR6
plays an important role in regulating leukocyte infiltration and function in the induction and progression of experimental autoimmune
encephalomyelitis
.
...
PMID:Resistance to myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis by death receptor 6-deficient mice. 1608 97
Survival and differentiation of oligodendrocytes are important for the myelination of central nervous system (CNS) axons during development and crucial for myelin repair in CNS demyelinating diseases such as multiple sclerosis. Here we show that
death receptor 6
(
DR6
) is a negative regulator of oligodendrocyte maturation.
DR6
is expressed strongly in immature oligodendrocytes and weakly in mature myelin basic protein (MBP)-positive oligodendrocytes. Overexpression of
DR6
in oligodendrocytes leads to caspase 3 (casp3) activation and cell death. Attenuation of
DR6
function leads to enhanced oligodendrocyte maturation, myelination and downregulation of casp3. Treatment with a
DR6
antagonist antibody promotes remyelination in both lysolecithin-induced demyelination and experimental autoimmune
encephalomyelitis
(EAE) models. Consistent with the
DR6
antagoinst antibody studies,
DR6
-null mice show enhanced remyelination in both demyelination models. These studies reveal a pivotal role for
DR6
signaling in immature oligodendrocyte maturation and myelination that may provide new therapeutic avenues for the treatment of demyelination disorders such as multiple sclerosis.
...
PMID:Death receptor 6 negatively regulates oligodendrocyte survival, maturation and myelination. 2179 16